NASDAQ: SUPN · Specialty & Generic Drug Manufacturers
Supernus (SUPN) fair value and price range
As of 16 Nov 2026, Faircurve's model values Supernus (SUPN) at $29.86 a share. The stock last closed at $28.96, which puts the model's fair value 3.1% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 18 Nov 2026. Supernus, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 16 Nov 2026 moved the fair value from $26.28 to $29.86 (+13.6%). The multiple the model anchors on moved, lifting the fair value: most of the move.
What the model makes of itThe price of $28.96 is 3.1% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 23 Feb 2027. Options prices imply a move of about 21% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give SUPN?
The calibrated range for SUPN over 63 trading days is $22.85 to $37.14. It sits around the last close, and its width comes from the volatility that SUPN's own options imply (72% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $17.51 to $48.43. In 50% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 16 Nov 2026
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases.
Faircurve's model puts the fair value at $29.86 a share, the midpoint of 2,000 simulations, on the run of 16 Nov 2026. The previous run, on 7 Nov 2026, gave $26.28, so the fair value moved +13.6%. In the model's own words, the multiple it anchors on moved, lifting the fair value: most of the move. The calibrated range over 63 trading days is $21.81 to $39.23. It is built around the price, using the volatility the stock's own options imply, and calibrated weekly against realised prices across 8,038 past valuations, refreshed 14 Nov 2026. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The sheet gives no quality score for the business. Alkermes plc (ALKS) is one of the comparable companies Faircurve's model compares it with, and it has a fair value of its own on the site. Seven further comparable companies have no verdict on this date: ANI Pharmaceuticals, Inc. (ANIP), Phibro Animal Health Corporation (PAHC), Pacira BioSciences, Inc. (PCRX), Amphastar Pharmaceuticals, Inc. (AMPH), Collegium Pharmaceutical, Inc. (COLL), Lantheus Holdings, Inc. (LNTH) and Amneal Pharmaceuticals, Inc. (AMRX). Faircurve first valued the company on 11 Jul 2026.
Written from the figures on this page for the 16 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does SUPN report earnings, and how has the stock reacted?
Supernus's next earnings report is scheduled for 23 Feb 2027. Companies can move their dates.
Options prices on 18 Nov 2026 imply a move of about 16.1% in either direction through the nearest expiry, about 29 days out. That is the size the market is pricing, not a direction. SUPN's 30 day implied volatility works out to about 20.7% over one month.
How SUPN moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 7.3%.
| Report date | Two session move |
|---|---|
| 3 Nov 2026 | -22.2% |
| 29 Oct 2026 | +1.7% |
| 3 Aug 2026 | -8.8% |
| 5 May 2026 | +5.8% |
| 30 Apr 2026 | -1.4% |
| 26 Feb 2026 | -2.8% |
| 24 Feb 2026 | +11.1% |
| 4 Nov 2025 | -15.4% |
How does SUPN compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Supernus in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ANIP ANI Pharmaceuticals, Inc. | $71.47 | $76.30 | +6.8% | Low evidence grade |
| PAHC Phibro Animal Health Corporation | $35.57 | $36.25 | +1.9% | Low evidence grade |
| PCRX Pacira BioSciences, Inc. | $36.48 | $36.71 | +0.6% | Low evidence grade |
| AMPH Amphastar Pharmaceuticals, Inc. | $29.71 | $29.29 | -1.4% | Low evidence grade |
| COLL Collegium Pharmaceutical, Inc. | $25.93 | $25.54 | -1.5% | Low evidence grade |
| LNTH Lantheus Holdings, Inc. | $102.00 | $100.64 | -1.3% | Data under review |
| AMRX Amneal Pharmaceuticals, Inc. | $21.88 | $19.34 | -11.6% | Low evidence grade |
| ALKS Alkermes plc | $46.85 | $46.51 | -0.7% | Fairly valued |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
Supernus at a glance
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases.
- Market value
- $1.7B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $2.3B
- Consensus revenue growth, next fiscal year
- +36.7%
- Analysts with estimates
- 2
- Beta to the US market
- 0.55
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Supernus on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for SUPN was $26.28. As of 16 Nov 2026 it is $29.86, a change of +13.6%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Supernus's valuation
Is Supernus stock undervalued or overvalued?
Faircurve's model puts SUPN's fair value at $29.86 a share against a last close of $28.96, as of 16 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is SUPN's fair value?
$29.86 a share as of 16 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $17.51 to $48.43.
What price range does the model give SUPN?
$22.85 to $37.14 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Supernus report earnings next?
The next report is scheduled for 23 Feb 2027. Companies can move their dates.
How much has SUPN moved on past earnings reports?
Across its last 8 reports the median two session move was 7.3%, ignoring direction. The largest was -22.2% around the report of 3 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for SUPN is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on SUPN
The model holds no idea open on SUPN today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on SUPN with their outcomes. A free account is enough.